Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

448
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
448
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

162
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
162
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

270
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
270
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial.

Neurourology and urodynamics·2024
Same author

Safety and Efficacy of Iltamiocel Cellular Therapy for the Treatment of Fecal Incontinence. Results of a Phase 1/2 Study.

Annals of surgery·2023
Same author

Autologous Muscle-Derived Cell Therapy for Swallowing Impairment in Patients Following Treatment for Head and Neck Cancer.

The Laryngoscope·2021
Same author

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.

Journal for immunotherapy of cancer·2019
Same author

Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype.

Journal of immunology research·2019
Same author

A druggable target for rescuing microRNA defects.

Bioorganic & medicinal chemistry letters·2016

Related Experiment Video

Updated: Feb 6, 2026

RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue
08:47

RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue

Published on: August 2, 2014

28.4K

Ribonucleases as Drug Targets.

Emanuele Canestrari1, Zain Paroo1

  • 1Department of Pharmacology, University of Illinois at Chicago, Chicago, IL 60612, USA.

Trends in Pharmacological Sciences
|August 27, 2018
PubMed
Summary
This summary is machine-generated.

New drug targets are urgently needed. Analysis revealed 122 human ribonucleases, critical signaling targets that can be leveraged for novel RNA-based therapeutics to improve patient outcomes.

Keywords:
RNAenzyme inhibitorribonucleasetarget identification

More Related Videos

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes
11:31

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes

Published on: February 18, 2020

8.3K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Related Experiment Videos

Last Updated: Feb 6, 2026

RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue
08:47

RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue

Published on: August 2, 2014

28.4K
Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes
11:31

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes

Published on: February 18, 2020

8.3K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • There is a critical need for novel drug targets across various disease indications.
  • The scarcity of effective drug targets leads to numerous drugs with limited clinical benefit.
  • Advances in RNA biology offer new therapeutic targets, but challenges remain for nucleic acid-based drugs.

Purpose of the Study:

  • To identify and characterize ribonucleases as a potential class of drug targets.
  • To explore the therapeutic potential of targeting ribonucleases for RNA-related diseases.
  • To expand therapeutic options by developing novel mechanisms of action.

Main Methods:

  • Analysis of the human proteome to identify all encoded ribonucleases.
  • Bioinformatic and biochemical characterization of the identified ribonucleases.
  • Comparative analysis with other enzyme classes (kinases, proteases, epigenetic enzymes).

Main Results:

  • Identified 122 distinct ribonucleases in the human proteome.
  • The identified ribonucleases play a crucial role in regulating the transcriptome.
  • These enzymes represent a conserved and essential component of cellular RNA processing.

Conclusions:

  • Ribonucleases constitute a druggable target class with significant therapeutic potential.
  • Targeting ribonucleases can capitalize on RNA mechanisms of disease for novel therapies.
  • Developing therapies against ribonucleases may lead to improved patient outcomes by expanding treatment options.